<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01626443</url>
  </required_header>
  <id_info>
    <org_study_id>MI-DCI</org_study_id>
    <nct_id>NCT01626443</nct_id>
  </id_info>
  <brief_title>Role of Myo-inositol and D-chiro Inositol on the Ovaric and Metabolic Functions</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lo.Li.Pharma s.r.l</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lo.Li.Pharma s.r.l</source>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of
      reproductive age and is characterized by menstrual abnormalities, clinical or biochemical
      hyperandrogenism, multiple abnormal cysts and enlarge ovaries. Women affected by PCOS often
      suffer of insulin resistance and of a compensatory hyperinsulinemia which put them at risk of
      developing several metabolic disorders. Inositol is a six-carbon polyol which has been
      characterized as an insulin sensitizer: it exists as nine different isomers and among them
      myo-inositol and D-chiroinositol are the most represented and studied in physiology and
      physiopathology. In particular, myo-inositol (MI) and D-chiro inositol (DCI) glycans
      administration has been reported to exert beneficial effects at metabolic, hormonal and
      ovarian levels.

      The aim of this randomized study is to evaluate the metabolic and ovaric effects of a
      six-month supplementation of myo-inositol and D-chiro-inositol on young women with PCOS and
      hyperinsulemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Menstrual cycle restoration</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Score hirsutism (Ferriman-Gallwey classification)</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum progesterone</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Testosterone level test</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral glucose tolerance test (OGTT)</measure>
    <time_frame>At 6 months</time_frame>
    <description>Evaluation of glycemia and insulinemia levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Homeostasis Model Assessment (HOMA-index)</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sex hormone binding globulin (SHBG) test</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Androstenediol level test</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Androstenedione level test</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Free Androgen Index (FAI) level test</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in diastolic blood pressure levels</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic blood pressure levels</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal ovarian size and morphology</measure>
    <time_frame>At 6 months</time_frame>
    <description>Ovarian ultrasound scan for the assessment of size and morphology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteinizing Hormone (LH) level test</measure>
    <time_frame>At 6 months</time_frame>
    <description>Analysis of LH levels should be performed between the 7th and the 10th day of the cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle Stimulating Hormone (FSH) level test</measure>
    <time_frame>At 6 months</time_frame>
    <description>Analysis of FSH levels should be performed between the 7th and the 10th day of the cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol (E2) level test</measure>
    <time_frame>At 6 months</time_frame>
    <description>Analysis of E2 levels should be performed between the 7th and the 10th day of the cycle</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>PCOS</condition>
  <arm_group>
    <arm_group_label>Folic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Inofolic Combi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol + D-chiro-inositol + Folic acid</intervention_name>
    <description>Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg) + Folic acid (200 mcg); 2 x die</description>
    <arm_group_label>Inofolic Combi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic acid</intervention_name>
    <description>Folic acid (200 mcg); 2 x die</description>
    <arm_group_label>Folic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOS

          -  Women aged between 14-40 years

          -  BMI &gt; 28

          -  Hyperinsulinemia

        Exclusion Criteria:

          -  Pre-existing secondary endocrine and metabolic disorders

          -  Pre-existing secondary adrenal disorders

          -  Pharmacologic treatment in the last 3 months before entering the study

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pisa - Department of Endocrinology</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999 Nov;84(11):4006-11.</citation>
    <PMID>10566641</PMID>
  </reference>
  <reference>
    <citation>Nestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol. 1997 May;15(2):111-22. Review.</citation>
    <PMID>9165656</PMID>
  </reference>
  <reference>
    <citation>Baillargeon JP, Nestler JE, Ostlund RE, Apridonidze T, Diamanti-Kandarakis E. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod. 2008 Jun;23(6):1439-46. doi: 10.1093/humrep/den097. Epub 2008 Mar 29.</citation>
    <PMID>18375940</PMID>
  </reference>
  <reference>
    <citation>Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999 Apr 29;340(17):1314-20.</citation>
    <PMID>10219066</PMID>
  </reference>
  <reference>
    <citation>Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod. 2002 Jun;17(6):1591-6.</citation>
    <PMID>12042283</PMID>
  </reference>
  <reference>
    <citation>Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72.</citation>
    <PMID>10523012</PMID>
  </reference>
  <reference>
    <citation>Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004 Feb;59(2):141-54. Review.</citation>
    <PMID>14752302</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2012</study_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>Metabolic disorders</keyword>
  <keyword>Ovarian functionality</keyword>
  <keyword>Myo-inositol</keyword>
  <keyword>D-chiro-inositol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

